Paris - Delayed Quote EUR

ABIONYX Pharma SA (ABNX.PA)

1.5680 -0.0480 (-2.97%)

At close: 5:35:13 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

Business Wire 6d ago

ABNX.PA
-2.97%
ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

Business Wire 26d ago

ABNX.PA
-2.97%
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Business Wire 1mo ago

ABNX.PA
-2.97%
ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

Business Wire 1mo ago

ABNX.PA
-2.97%
ABIONYX Pharma: Half Year Results 2026

Business Wire 1mo ago

ABNX.PA
-2.97%
ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

Business Wire 1mo ago

ABNX.PA
-2.97%
ABLD.PA
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026

Business Wire 2mo ago

ABNX.PA
-2.97%
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Business Wire 3mo ago

ABNX.PA
-2.97%
ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

Business Wire 4mo ago

ABNX.PA
-2.97%
ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million

Business Wire 1mo ago

ABNX.PA
-2.97%
ABLD.PA
Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Business Wire 2mo ago

ABNX.PA
-2.97%
ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma

Business Wire 1mo ago

ABLD.PA

ABNX.PA
-2.97%

Performance Overview

Return	ABNX.PA	CAC 40 (^FCHI)
YTD	-58.57%	-1.25%
1-Year	-62.22%	-0.90%
3-Year	+18.79%	+13.98%

U.S. markets close in 3h 24m

ABIONYX Pharma SA (ABNX.PA)

ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

ABIONYX Pharma: Half Year Results 2026

ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million

Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma